ELVN
ELVN
NASDAQ · Pharmaceuticals

Enliven Therapeutics Inc

$60.46
+0.19 (+0.32%)
As of Aug 8, 10:05 PM ET ·
Analyst Consensus
Strong Buy
18
Analysts
High
Coverage
Buy 17 94%
Hold 1 6%
Sell 0 0%
Price Target
Analyst Price Target -47.6% upside
Low Target $20.91
Average Target $31.67
High Target $36.06
Current Price $60.46
Current
$60.46
Target
$31.67
$20.91 $31.67 avg $36.06
Scenario Analysis
Bear Case
$20.91
-65.4%
Low target
Base Case
$31.67
-47.6%
Avg target
Bull Case
$36.06
+-40.4%
High target
Risk/Reward
0.6x
Unfavorable
Price in Context
52-Week High
$62.32
-3.0% from high
52-Week Low
$14.79
+308.9% from low
Target vs 52W High
$31.67
-49.2% vs high
Next Earnings Report
Aug 19, 2026
9d
until earnings
EPS Est: $-0.41
Earnings in 9 days. Analyst targets may shift significantly after the report.
Peer Consensus — Pharmaceuticals
Stock Consensus Analysts Buy % Target Upside
LLY
Eli Lilly and Co.
Strong Buy 38 79% $1,330.33 +12.2%
RDY
Dr. Reddy's Laboratories
Sell 44 52% +0.0%
JNJ
Johnson & Johnson
Buy 31 68% $299.55 +15.5%
MRK
Merck & Co. Inc.
Buy 36 69% $159.27 +23.9%
PFE
Pfizer Inc.
Hold 36 42% $33.90 +26.7%
BMY
Bristol-Myers Squibb Co
Hold 35 40% $174.50 +169.6%
RPRX
Royalty Pharma Plc- Cl A
Strong Buy 16 88% $36.26 -36.1%
ZTS
Zoetis Inc
Hold 24 54% $209.87 +188.8%